Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Exclusion Criteria

• •Prior or concurrent systemic anticancer therapy (immunotherapy, hormonal therapy, biological therapy, or chemotherapy) for pancreatic cancer
• •Prior or concurrent radiation therapy for pancreatic cancer
• •Pregnant or lactating patients
• •M1 pancreatic cancer
• •Concurrent congestive heart failure, unstable angina pectoris, or M1 within the 6 months before first study treatment
• •Uncontrolled hypertension or high-risk uncontrolled arrhythmias
• •Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
• •Diagnosed or suspected congenital long QT syndrome
• •Prolonged QTc interval on pre-entry electrocardiogram (\> 450 msec)
• •History of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent
• •Past or current history of neoplasm other than pancreatic adenocarcinoma, except for: curatively treated non-melanoma skin cancer; in situ carcinoma of the cervix; other cancer curatively treated and with no evidences of disease for at least 1 year
• •Concurrent treatment with other experimental drugs or treatment with investigational drugs within 30 days of first study treatment
• •Currently receiving drugs with known significant CYP 3A4 inhibitory effects (such as ketoconazole, itraconazole, troleandomycin, erythromycin, diltiazem, verapamil, ritonavir, indinavir)
• •Concurrent administration with inducers of CYP 3A4 may result in a lower exposure to dasatinib and are therefore not allowed (e.g., phenytoin, carbamazepine, rifampicin, phenobarbital, pentobarbital, or St John's Wort)
• •Known allergy reactions to dasatinib or gemcitabine or excipients used in the study
• •History of significant bleeding disorders unrelated to cancer, including: diagnosed congenital bleeding disorders (e.g., Von Willebrand's disease); diagnosed acquired bleeding disorder within 1 year (e.g., acquired anti-factor VIII antibodies); ongoing or recent (=\< 3 months) significant gastrointestinal bleeding
• •Patients currently taking drugs that are generally accepted to have a risk of causing Torsades De Pointes including: quinidine, procainamide, disopyramide; amiodarone, sotalol, ibutilide, dofetilide; erythromycins, clarithromycin; chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide; cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine
• •Concurrent treatment with intravenous bisphosphonates; prior treatment should be stopped at least 2 weeks before first dose of study treatment
• •Concurrent medical condition which may increase the risk of toxicity, including pleural or pericardial effusion or any grade
• •Active uncontrolled infection requiring parenteral antimicrobials